Torrent Pharma Vista Division Product List

Has acquired Bio-Pharm, a generic and overthe-counter drugmaker based in Levittown, Pennsylvania, for an undisclosed sum. “This acquisition is an important step for increasing Torrent’s presence in the United States, is consistent with our strategy of dosage form diversification, and provides us with new capabilities including manufacturing and R&D presence in the USA,” the Ahmedabad-based company said on Thursday. Bio-Pharm, Inc. (BPI), which has a 75,000 sqft manufacturing facility, boasts of 10 abbreviated new drug applications (ANDAs) already approved by the (FDA). It has another 10 ANDAs — or applications for approval of a generic drug product — under review at while its partners have an additional 17 products under development. Torrent Pharma said it plans further investments to expand the BPI facilities, including its research and development (R&D) capabilities, and increase the number of product filings from BPI. This is the third acquisition for Torrent Pharma in the last three years.

Last year it had acquired business of to strengthen its presence in the domestic market.

Vista Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in the formulation of pharmaceutical products. This division is a primary contributor to the domestic sales of Torrent Pharmaceuticals. Policy Disclaimer Investor Communication List of our GST registration number.

Torrent Pharma, the flagship company of Torrent Group, is ranked amongst the top pharma companies of India. It is a dominant player in the therapeutic areas of cardiovascular (CV) and central nervous system (CNS) and has achieved significant presence in gastro-intestinal, diabetology, anti-infective and pain management segments. It has also forayed into the therapeutic segments of nephrology and oncology while also strengthening its focus on gynecology and pediatric segments. Right from pioneering niche marketing in India to earning the sobriquet of ‘the Company with the most first launches’, Torrent Pharma has always remained ahead of its competition.

Torrent Pharma’s competitive advantage stems from its world-class manufacturing facilities, advanced R&D capabilities, extensive domestic network and a widespread global presence. It has three world-class manufacturing facilities at Indrad (Gujarat), Baddi (Himachal Pradesh) and Sikkim. The facilities are approved by USFDA, WHO, MHRA, TGA and other global regulatory bodies. A new facility is taking shape at Dahej SEZ in Western India, which will cater to the international markets. Torrent Pharma is the sole manufacturer of Insulin Formulations for Novo Nordisk in India since the early ‘90s and has also set up a dedicated formulation and packaging facility for Insulin.

Source: Torrent Pharmaceuticals Ltd: Leader in the pharmaceutical industry 2015 Torrent Pharma recognized as the Most Promising Company of the Year at the 10th CNBC TV18 India Business Leader Awards 2014. 2014 Acquired Elder Pharma’s Indentified Indian Branded Formulation Business in India and Nepal.

2011 Forayed into oncology segment. 2006 The API and formulations manufacturing facilities located at Indrad (Gujarat, India) got USFDA approval. 2000 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility. Updated: January, 2015. • • • • • • • • • • • • • • • • • • • • • • Copyright © 2010-2019 India Brand Equity Foundation All material, information, data, images or content on this website is subject to copyright or other applicable intellectual property laws and no part of it can be reproduced in any form (including paper or electronic form) without prior written consent and approval from IBEF. Infringements are subject to prosecution under the applicable laws.